In vivo type 1 cannabinoid receptor availability in Alzheimer's disease

被引：50

作者：

Ahmad, Rawaha ^{[1
,2
]}

Goffin, Karolien ^{[1
,2
]}

Van den Stock, Jan ^{[3
,4
]}

De Winter, Francois-Laurent ^{[3
,4
]}

Cleeren, Evy ^{[1
,2
]}

Bormans, Guy ^{[5
]}

Tournoy, Jos ^{[1
,6
]}

Persoons, Philippe ^{[3
,4
]}

Van Laere, Koen ^{[1
,2
]}

Vandenbulcke, Mathieu ^{[3
,4
]}

机构：

[1] Katholieke Univ Leuven Hosp, B-3000 Louvain, Belgium

[2] Katholieke Univ Leuven, Dept Imaging & Pathol, Louvain, Belgium

[3] Katholieke Univ Leuven Hosp, Dept Old Age Psychiat, B-3000 Louvain, Belgium

[4] Katholieke Univ Leuven, Dept Neurosci, Louvain, Belgium

[5] Katholieke Univ Leuven, Lab Radiopharm, Louvain, Belgium

[6] Katholieke Univ Leuven, Dept Clin & Expt Med, Louvain, Belgium

来源：

EUROPEAN NEUROPSYCHOPHARMACOLOGY | 2014年 / 24卷 / 02期

关键词：

Alzheimer's disease; Cannabinoid receptor; Amyloid; PET scan; MMSE; ApoE; HUNTINGTONS-DISEASE; AMYLOID-DEPOSITION; COGNITIVE IMPAIRMENT; BASAL GANGLIA; CB1; RECEPTORS; HUMAN BRAIN; PET TRACER; A-BETA; DEMENTIA; MEMORY;

D O I：

10.1016/j.euroneuro.2013.10.002

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

The endocannabinoid system (ECS) is an important modulatory and potentially neuroprotective homeostatic system in the brain. In Alzheimer's disease (AD), the role of type 1 cannabinoid receptor (CB1R) is unclear, with contradictory findings in post-mortem studies showing upregulation, down-regulation or unchanged CB1R status. We have investigated CB1R availability in vivo in patients with AD, in relation to amyloid deposition, cognitive functioning and apolipoprotein E (ApoE) genotype. Eleven AD patients and 7 healthy volunteers (HV) underwent combined [F-18]MK-9470 PETand [C-11]PlB PET scans to assess CB1R availability and amyloid deposition, respectively, and T1 volumetric MRI for partial volume correction. We found no difference in CB1R availability between AD and HV, VOI-based fractional uptake values (FUR) were 0.043 +/- 0.01 for AD and 0.045 +/- 0.01 for controls (p=0.9). CB1R availability did not correlate with neuropsychological test scores and was not modulated by ApoE genotype. As expected, global [C-11]PlB SUVR (standardized uptake value ratio) was increased in AD (SUVR 1.9 +/- 0.3) compared to HV (1.2 +/- 0.1) with p < 0.001, but no correlation was found between amyloid beta (A beta) deposition and CB1R availability. In conclusion, we found no in vivo evidence for a difference in CB1R availability in AD compared to age-matched controls. Taken together with recently reported in vivo CB1R changes in Parkinson's and Huntington's disease, these data suggest that the CB1R is differentially involved in neurodegenerative disorders. (C) 2013 Elsevier B.V. and ECNP. All rights reserved.

引用

页码：242 / 250

页数：9

共 48 条

[11] [125I]SD-7015 reveals fine modalities of CB1 cannabinoid receptor density in the prefrontal cortex during progression of Alzheimer's disease [J].

Farkas, Szabolcs ;

Nagy, Katalin ;

Palkovits, Miklos ;

Kovacs, Gabor G. ;

Jia, Zhisheng ;

Donohue, Sean ;

Pike, Vic ;

Halldin, Christer ;

Mathe, Domokos ;

Harkany, Tibor ;

Gulyas, Balazs ;

Csiba, Laszlo .

NEUROCHEMISTRY INTERNATIONAL, 2012, 60 (03) :286-291

[12]

Galasko D, 1997, ALZ DIS ASSOC DIS, V11, pS33

[13] Cannabinoids and Parkinson's Disease [J].

Garcia-Arencibia, Moises ;

Garcia, Concepcion ;

Fernandez-Ruiz, Javier .

CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS, 2009, 8 (06) :432-439

[14] LOSS OF CANNABINOID RECEPTORS IN THE SUBSTANTIA-NIGRA IN HUNTINGTONS-DISEASE [J].

GLASS, M ;

FAULL, RLM ;

DRAGUNOW, M .

NEUROSCIENCE, 1993, 56 (03) :523-527

[15] The pattern of neurodegeneration in Huntington's disease:: A comparative study of cannabinoid, dopamine, adenosine and GABAA receptor alterations in the human basal ganglia in Huntington's disease [J].

Glass, M ;

Dragunow, M ;

Faull, RLM .

NEUROSCIENCE, 2000, 97 (03) :505-519

[16]

Horti AG, 2006, J NUCL MED, V47, P1689

[17] The serotonergic system in ageing and Alzheimer's disease [J].

Julio Rodriguez, Jose ;

Noristani, Harun N. ;

Verkhratsky, Alexei .

PROGRESS IN NEUROBIOLOGY, 2012, 99 (01) :15-41

[18] The diagnostic accuracy of an incidental memory modification of the Boston Naming Test (memo-BNT) in differentiating between normal aging and mild Alzheimer's disease [J].

Karrasch, Mira ;

Myllyniemi, Anna ;

Latvasalo, Linda ;

Soderholm, Carina ;

Ellfolk, Ulla ;

Laine, Matti .

CLINICAL NEUROPSYCHOLOGIST, 2010, 24 (08) :1355-1364

[19] Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B [J].

Klunk, WE ;

Engler, H ;

Nordberg, A ;

Wang, YM ;

Blomqvist, G ;

Holt, DP ;

Bergström, M ;

Savitcheva, I ;

Huang, GF ;

Estrada, S ;

Ausén, B ;

Debnath, ML ;

Barletta, J ;

Price, JC ;

Sandell, J ;

Lopresti, BJ ;

Wall, A ;

Koivisto, P ;

Antoni, G ;

Mathis, CA ;

Långström, B .

ANNALS OF NEUROLOGY, 2004, 55 (03) :306-319

[20] Increased cannabinoid CB1 receptor binding and activation of GTP-binding proteins in the basal ganglia of patients with Parkinson's syndrome and of MPTP-treated marmosets [J].

Lastres-Becker, I ;

Cebeira, M ;

de Ceballos, ML ;

Zeng, BY ;

Jenner, P ;

Ramos, JA ;

Fernández-Ruiz, JJ .

EUROPEAN JOURNAL OF NEUROSCIENCE, 2001, 14 (11) :1827-1832

← 1 2 3 4 5 →